NAMS Menopause
Certification ACTUAL
EXAM | Version 1 |
Evidence-Based
Solutions
PART 0: THE Table of Contents
Section Cognitive Tier Page / Focus Area
PART I: THE Preview Command Fundamentals Critical Axioms & Cheat Sheet
PART II: THE ELITE TEST
BANK
Tier 1 Foundational Syntax & Questions 1 – 10: Definitions,
Application Core Formulas, Primary
Theories
Tier 2 Complex Application & Questions 11 – 20: Variable
Simulation Changes, Immediate Actions,
Outcomes
Tier 3 Grandmaster Synthesis Questions 21 – 30: High-Stakes
Scenarios, Competing
Concepts
PART I: THE Preview
The mastery of this document forges the fundamental divide between standard clinical
competency and elite, global-standard academic intuition. Rigorous internalization of these
frameworks translates directly into precise, evidence-based interventions that protect patient
longevity while optimizing quality of life during the menopausal transition.
● The 2025/2026 FDA MHT Directive: The United States Food and Drug Administration
(FDA) definitively removed legacy black-box warnings regarding cardiovascular disease,
breast cancer, and probable dementia for Menopausal Hormone Therapy (MHT). The
absolute contraindication of unopposed systemic estrogen in patients with an intact uterus
(endometrial cancer risk) strictly remains.
● The Fezolinetant LFT Protocol: Hepatic function must be assessed at baseline, monthly
for the first 3 months, and at months 6 and 9. Therapy must be aborted IMMEDIATELY if
, transaminases exceed 3x the upper limit of normal (ULN) combined with bilirubin > 2x
ULN, or if transaminases strictly exceed 5x ULN.
● The 2023 PCOS Diagnostic Evolution: In adult diagnostics, serum Anti-Müllerian
Hormone (AMH) replaces ultrasonography as a marker for polycystic ovarian morphology
(PCOM); concurrent ordering of both is forbidden. For adolescents, imaging and AMH are
strictly prohibited; diagnosis mandates clinical/biochemical hyperandrogenism combined
with oligo-anovulation.
● The Bisphosphonate Holiday Threshold: Patients at low-to-moderate fracture risk
require a 2- to 3-year drug holiday after 3 to 5 years of oral bisphosphonate therapy.
High-risk patients mandate 10 years of oral therapy (or 6 years intravenous) before a 1- to
2-year holiday, frequently bridged with anabolic agents.
● The Norgestrel 0.075 mg (Opill) Window: Progestin-only pills (POPs) operate on a
ruthless 3-hour adherence margin. A delay exceeding 3 hours mandates immediate
dosing and 48 hours of barrier backup contraception.
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: Following the November 2025 and February 2026 FDA regulatory updates to Menopausal
Hormone Therapy (MHT) labeling, which of the following boxed warnings was explicitly
RETAINED on systemic estrogen-alone products? A) The increased risk of probable dementia
in women aged 65 years and older. B) The increased risk of cardiovascular disease, including
myocardial infarction and stroke. C) The increased risk of endometrial cancer in women with an
intact uterus. D) The increased risk of invasive breast cancer following prolonged administration.
● The Answer: C (The increased risk of endometrial cancer in women with an intact
uterus.)
● Distractor Analysis:
○ A is incorrect: The FDA explicitly removed the warning regarding probable dementia
from the boxed warnings of MHT products, recognizing that legacy data from the
Women's Health Initiative (WHI) was applied inappropriately to younger,
symptomatic cohorts.
○ B is incorrect: The warning for cardiovascular disease was removed from the boxed
warning label across all four categories of MHT products, reflecting current
evidence that MHT initiated within 10 years of menopause reduces all-cause
mortality.
○ D is incorrect: The breast cancer boxed warning was removed in the 2026 label
update, as randomized data established no significant increase in risk—and
potentially a reduction—when estrogen-alone therapy is utilized in appropriate
populations.
The Mentor's Analysis: The FDA’s 2026 labeling update represents a historic paradigm shift,
dismantling decades of fear-based prescribing by removing cardiovascular disease, breast
cancer, and dementia from the MHT boxed warnings. However, the physiological law governing
endometrial proliferation remains absolute: unopposed systemic estrogen in a patient with a
uterus drives hyperplasia and malignancy. Professional/Academic Intuition: Never prescribe
unopposed systemic estrogen to a patient with an intact uterus; the endometrial
hyperplasia boxed warning remains the non-negotiable exception to the 2026 FDA
, de-escalation.
Q2: A 52-year-old female is prescribed fezolinetant 45 mg daily for severe vasomotor
symptoms. Based on current FDA and European Medicines Agency (EMA) directives, what is
the MOST ACCURATE required schedule for hepatic laboratory testing? A) Baseline, then
monthly for the first 3 months, followed by tests at 6 and 9 months. B) Baseline, followed by
testing every 3 months for the first year of therapy. C) Baseline only, unless the patient becomes
symptomatic with jaundice or right upper quadrant pain. D) Baseline, then monthly for the first 6
months, followed by annual testing.
● The Answer: A (Baseline, then monthly for the first 3 months, followed by tests at 6 and 9
months.)
● Distractor Analysis:
○ B is incorrect: Testing every 3 months is insufficient during the high-risk initiation
phase. The first 3 months require monthly monitoring to capture early transaminase
elevations.
○ C is incorrect: This represents a dangerous legacy approach. Fezolinetant has
been linked to asymptomatic transaminase elevations and rare cases of severe
drug-induced liver injury (DILI), mandating strict, scheduled serological surveillance
regardless of symptom presentation.
○ D is incorrect: Monthly testing for 6 months exceeds the FDA/EMA mandate and
creates unnecessary healthcare burdens. The standard protocol steps down to
month 6 and month 9 after the initial 90-day window.
The Mentor's Analysis: Fezolinetant acts as a neurokinin-3 (NK3) receptor antagonist,
effectively bypassing the estrogen pathway to neutralize vasomotor symptoms. However, its
hepatic metabolism profile demands rigorous surveillance. The critical window for hepatotoxicity
occurs early in the treatment course. Professional/Academic Intuition: Fezolinetant requires
an exact 1, 2, 3, 6, and 9-month hepatic monitoring sequence; failure to establish
baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALP), and bilirubin constitutes a critical breach of the standard of
care.
Q3: According to the 2023 International Evidence-based Guideline for the Assessment and
Management of Polycystic Ovary Syndrome (PCOS), which diagnostic methodology is MOST
APPROPRIATE for identifying polycystic ovarian morphology (PCOM) in an adult female who
presents with isolated clinical hyperandrogenism? A) Concurrent use of both pelvic
ultrasonography and serum Anti-Müllerian Hormone (AMH) to ensure diagnostic redundancy. B)
Pelvic ultrasonography exclusively, as AMH levels are heavily influenced by chronologic aging.
C) Serum Anti-Müllerian Hormone (AMH) measurement or pelvic ultrasonography, utilized as
mutually exclusive alternative modalities. D) Endometrial biopsy to rule out hyperplasia prior to
confirming the morphological parameters of PCOS.
● The Answer: C (Serum Anti-Müllerian Hormone (AMH) measurement or pelvic
ultrasonography, utilized as mutually exclusive alternative modalities.)
● Distractor Analysis:
○ A is incorrect: The guidelines strictly prohibit ordering both tests concurrently.
Utilizing both AMH and ultrasound significantly increases the risk of over-diagnosis
and represents a wasteful allocation of medical resources.
○ B is incorrect: While ultrasound was the historical gold standard under the original
Rotterdam criteria, the 2023 update explicitly elevates AMH as a valid, stand-alone
alternative to ultrasound for defining PCOM in adults.
○ D is incorrect: While endometrial protection is a long-term management
Certification ACTUAL
EXAM | Version 1 |
Evidence-Based
Solutions
PART 0: THE Table of Contents
Section Cognitive Tier Page / Focus Area
PART I: THE Preview Command Fundamentals Critical Axioms & Cheat Sheet
PART II: THE ELITE TEST
BANK
Tier 1 Foundational Syntax & Questions 1 – 10: Definitions,
Application Core Formulas, Primary
Theories
Tier 2 Complex Application & Questions 11 – 20: Variable
Simulation Changes, Immediate Actions,
Outcomes
Tier 3 Grandmaster Synthesis Questions 21 – 30: High-Stakes
Scenarios, Competing
Concepts
PART I: THE Preview
The mastery of this document forges the fundamental divide between standard clinical
competency and elite, global-standard academic intuition. Rigorous internalization of these
frameworks translates directly into precise, evidence-based interventions that protect patient
longevity while optimizing quality of life during the menopausal transition.
● The 2025/2026 FDA MHT Directive: The United States Food and Drug Administration
(FDA) definitively removed legacy black-box warnings regarding cardiovascular disease,
breast cancer, and probable dementia for Menopausal Hormone Therapy (MHT). The
absolute contraindication of unopposed systemic estrogen in patients with an intact uterus
(endometrial cancer risk) strictly remains.
● The Fezolinetant LFT Protocol: Hepatic function must be assessed at baseline, monthly
for the first 3 months, and at months 6 and 9. Therapy must be aborted IMMEDIATELY if
, transaminases exceed 3x the upper limit of normal (ULN) combined with bilirubin > 2x
ULN, or if transaminases strictly exceed 5x ULN.
● The 2023 PCOS Diagnostic Evolution: In adult diagnostics, serum Anti-Müllerian
Hormone (AMH) replaces ultrasonography as a marker for polycystic ovarian morphology
(PCOM); concurrent ordering of both is forbidden. For adolescents, imaging and AMH are
strictly prohibited; diagnosis mandates clinical/biochemical hyperandrogenism combined
with oligo-anovulation.
● The Bisphosphonate Holiday Threshold: Patients at low-to-moderate fracture risk
require a 2- to 3-year drug holiday after 3 to 5 years of oral bisphosphonate therapy.
High-risk patients mandate 10 years of oral therapy (or 6 years intravenous) before a 1- to
2-year holiday, frequently bridged with anabolic agents.
● The Norgestrel 0.075 mg (Opill) Window: Progestin-only pills (POPs) operate on a
ruthless 3-hour adherence margin. A delay exceeding 3 hours mandates immediate
dosing and 48 hours of barrier backup contraception.
PART II: THE ELITE TEST BANK
Tier 1: Foundational Syntax & Application
Q1: Following the November 2025 and February 2026 FDA regulatory updates to Menopausal
Hormone Therapy (MHT) labeling, which of the following boxed warnings was explicitly
RETAINED on systemic estrogen-alone products? A) The increased risk of probable dementia
in women aged 65 years and older. B) The increased risk of cardiovascular disease, including
myocardial infarction and stroke. C) The increased risk of endometrial cancer in women with an
intact uterus. D) The increased risk of invasive breast cancer following prolonged administration.
● The Answer: C (The increased risk of endometrial cancer in women with an intact
uterus.)
● Distractor Analysis:
○ A is incorrect: The FDA explicitly removed the warning regarding probable dementia
from the boxed warnings of MHT products, recognizing that legacy data from the
Women's Health Initiative (WHI) was applied inappropriately to younger,
symptomatic cohorts.
○ B is incorrect: The warning for cardiovascular disease was removed from the boxed
warning label across all four categories of MHT products, reflecting current
evidence that MHT initiated within 10 years of menopause reduces all-cause
mortality.
○ D is incorrect: The breast cancer boxed warning was removed in the 2026 label
update, as randomized data established no significant increase in risk—and
potentially a reduction—when estrogen-alone therapy is utilized in appropriate
populations.
The Mentor's Analysis: The FDA’s 2026 labeling update represents a historic paradigm shift,
dismantling decades of fear-based prescribing by removing cardiovascular disease, breast
cancer, and dementia from the MHT boxed warnings. However, the physiological law governing
endometrial proliferation remains absolute: unopposed systemic estrogen in a patient with a
uterus drives hyperplasia and malignancy. Professional/Academic Intuition: Never prescribe
unopposed systemic estrogen to a patient with an intact uterus; the endometrial
hyperplasia boxed warning remains the non-negotiable exception to the 2026 FDA
, de-escalation.
Q2: A 52-year-old female is prescribed fezolinetant 45 mg daily for severe vasomotor
symptoms. Based on current FDA and European Medicines Agency (EMA) directives, what is
the MOST ACCURATE required schedule for hepatic laboratory testing? A) Baseline, then
monthly for the first 3 months, followed by tests at 6 and 9 months. B) Baseline, followed by
testing every 3 months for the first year of therapy. C) Baseline only, unless the patient becomes
symptomatic with jaundice or right upper quadrant pain. D) Baseline, then monthly for the first 6
months, followed by annual testing.
● The Answer: A (Baseline, then monthly for the first 3 months, followed by tests at 6 and 9
months.)
● Distractor Analysis:
○ B is incorrect: Testing every 3 months is insufficient during the high-risk initiation
phase. The first 3 months require monthly monitoring to capture early transaminase
elevations.
○ C is incorrect: This represents a dangerous legacy approach. Fezolinetant has
been linked to asymptomatic transaminase elevations and rare cases of severe
drug-induced liver injury (DILI), mandating strict, scheduled serological surveillance
regardless of symptom presentation.
○ D is incorrect: Monthly testing for 6 months exceeds the FDA/EMA mandate and
creates unnecessary healthcare burdens. The standard protocol steps down to
month 6 and month 9 after the initial 90-day window.
The Mentor's Analysis: Fezolinetant acts as a neurokinin-3 (NK3) receptor antagonist,
effectively bypassing the estrogen pathway to neutralize vasomotor symptoms. However, its
hepatic metabolism profile demands rigorous surveillance. The critical window for hepatotoxicity
occurs early in the treatment course. Professional/Academic Intuition: Fezolinetant requires
an exact 1, 2, 3, 6, and 9-month hepatic monitoring sequence; failure to establish
baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST),
alkaline phosphatase (ALP), and bilirubin constitutes a critical breach of the standard of
care.
Q3: According to the 2023 International Evidence-based Guideline for the Assessment and
Management of Polycystic Ovary Syndrome (PCOS), which diagnostic methodology is MOST
APPROPRIATE for identifying polycystic ovarian morphology (PCOM) in an adult female who
presents with isolated clinical hyperandrogenism? A) Concurrent use of both pelvic
ultrasonography and serum Anti-Müllerian Hormone (AMH) to ensure diagnostic redundancy. B)
Pelvic ultrasonography exclusively, as AMH levels are heavily influenced by chronologic aging.
C) Serum Anti-Müllerian Hormone (AMH) measurement or pelvic ultrasonography, utilized as
mutually exclusive alternative modalities. D) Endometrial biopsy to rule out hyperplasia prior to
confirming the morphological parameters of PCOS.
● The Answer: C (Serum Anti-Müllerian Hormone (AMH) measurement or pelvic
ultrasonography, utilized as mutually exclusive alternative modalities.)
● Distractor Analysis:
○ A is incorrect: The guidelines strictly prohibit ordering both tests concurrently.
Utilizing both AMH and ultrasound significantly increases the risk of over-diagnosis
and represents a wasteful allocation of medical resources.
○ B is incorrect: While ultrasound was the historical gold standard under the original
Rotterdam criteria, the 2023 update explicitly elevates AMH as a valid, stand-alone
alternative to ultrasound for defining PCOM in adults.
○ D is incorrect: While endometrial protection is a long-term management
